Table 3 Data collection schedule.
Week | ||||||||
|---|---|---|---|---|---|---|---|---|
–6 | –2 | 0 | 6 | 12 | 24 | 36 | 48 | |
Enrolment | ||||||||
Informed consent | x | |||||||
DRCx2, PACx2, ARR x2, UEC, BhCG (if relevant), HBA1C, PTH, calcium, vitamin D, TSH, plasma metanephrines, 24-h urinary cortisol, and saline suppression test. | x | |||||||
Randomization | x | |||||||
Intervention | ||||||||
Active: MRA | ||||||||
Control: standard antihypertensives | ||||||||
Assessment | ||||||||
BMI, age, sex, ethnicity, smoking status, ethanol intake, OSA screening | x | x (weight only) | ||||||
Mean clinic blood pressure | x | x | x | x | x | x | x | |
PAC, DRC, ARR, UEC | x | x | x | x | x | |||
Fasting glucose, fasting lipid profile, liver function tests | x | x | ||||||
PTH, calcium, vitamin D | x | |||||||
24-h urine sodium, potassium, calcium, aldosterone, and albumin | x | x | ||||||
24-h urine steroid profile | x | |||||||
FBE, CRP, BNP | x | x | ||||||
Plasma steroid profile | x | |||||||
Plasma and urine biobank sample | x | x | ||||||
Monocyte gene expression profile | x | |||||||
ABPM | x | x | ||||||
TTE | x | x | ||||||
Endothelial function | x | x | ||||||
QOL (SF-36 questionnaire) | x | x | ||||||
Compliance assessment | x | x | x | x | x | |||
Adverse effect monitoring | x | x | x | x | x | |||